AstraZeneca's (AZN) Nasal Spray Influenza Vaccine Fluenz Receives Trivalent Marketing Authorization in Europe
Rapid Transition to Trivalent Vaccine in Accordance with WHO Recommendations
The European Medicines Agency (EMA) has approved the transition of AstraZeneca's (AZN) nasal spray influenza vaccine, Fluenz, to a trivalent formulation. This approval follows the World Health Organization's (WHO) recommendation to remove the B/Yamagata lineage of influenza virus, which has not been detected globally since 2020, from vaccine components. As a result, the existing quadrivalent vaccine, Fluenz Tetra, is undergoing commercial discontinuation and will be fully withdrawn from the European market by August 2025, with the new trivalent Fluenz replacing it. This strategic decision is evaluated as a proactive response to regulatory guidance to maintain public health safety and maximize manufacturing efficiency.
Differentiated Pharmacological Mechanism and Advantages of the Nasal Spray Formulation
Fluenz is developed as a live attenuated influenza vaccine (LAIV) targeting influenza A (H1N1, H3N2) and B (Victoria lineage) viruses. Unlike traditional injectable inactivated vaccines, it is administered directly via nasal spray, inducing local mucosal immunity and demonstrating strong protective capabilities by blocking the virus at its point of entry. It provides high dosing convenience for pediatric and adolescent patients with needle phobia and can be extended to home-administration (Home-administration) formulations, making it a recognized alternative in pediatric medical settings.
Securing Competitive Advantage in the Global Influenza Vaccine Market
The global influenza vaccine market is estimated to be between $7.6 billion and $9.2 billion, with traditional injectable vaccines such as Sanofi's (SNY) Fluzone and GSK's Fluarix dominating over half of the market. AstraZeneca's Fluenz (marketed as FluMist in the U.S.) leverages its unique nasal spray formulation to achieve stable global annual sales of $272 million as of 2025. This trivalent transition approval allows for a faster portfolio realignment compared to competitors, reinforcing its market share in the injectable alternative segment and securing supply chain leadership.
Mid-to-Long-Term Portfolio Restructuring in Pediatric Vaccines
This European marketing authorization is more than a license renewal; it is a significant milestone ensuring the sustainability of AstraZeneca's Vaccines & Immune Therapies business. By removing unnecessary antigens, it reduces production costs and proactively controls adverse reaction risks, thereby further enhancing vaccine acceptance among pediatric populations. In the mid-to-long term, it is expected to provide a competitive edge in National Immunization Program (NIP) tenders, serving as a key growth driver for AstraZeneca's cash cow franchise.
AstraZeneca's (AZN) trivalent nasal spray vaccine Fluenz receiving European marketing authorization is a regulatory response to WHO's B/Yamagata recommendation and a necessary step to maintain market share in the approximately $9.2 billion global influenza vaccine market. This approval ensures the Fluenz franchise, generating annual sales of $272 million, can be stably supplied in the European market even after the quadrivalent version is discontinued. It will strengthen AstraZeneca's dominance in the pediatric and adolescent market by maximizing the unique convenience of the nasal spray formulation amid competition with injectable vaccine manufacturers such as Sanofi's (SNY) Fluzone and GSK's Fluarix. In the mid-to-long term, cost savings from formulation simplification are expected, and it is projected to secure a key differentiating advantage in National Immunization Program (NIP) procurement tenders.
Source: EMA (ema)